Engineered immune cells take on rare protein disease in major trial
Disease control
Not yet recruiting
This phase 3 trial compares an experimental CAR-T cell therapy, NXC-201, with a standard drug combination (daratumumab plus CyBorD) in people newly diagnosed with AL amyloidosis, a rare condition where abnormal proteins damage organs. Participants receive either a single infusion…
Phase: PHASE3 • Sponsor: Nexcella Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC